Europe minimal residual disease (MRD) testing market was valued at $ 265.6 million in 2021 and will grow by 11.8% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 37 tables and 55 figures, this 115-page report “Europe Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country.
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 37 tables and 55 figures, this 115-page report “Europe Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Five Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country.
Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Services
- Test Kits & Consumables
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Non-Hodgkin's Lymphoma (NHL)
- DLBCL
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Peripheral T-cell Lymphoma
- Mantle Cell Lymphoma
- Other NHLs
- Multiple Myeloma (MM)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphoblastic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Hodgkin's Lymphoma (HL)
- Solid Tumor
- Other Applications
By Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other Technologies
By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Hospitals and Clinics
- Research Institutions
- Diagnostic Laboratories
- Other End Users
Geographically, the following national/local markets are fully investigated:
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Frequently Asked Questions about the European Minimal Residual Disease Testing Market
What is the estimated value of the European Minimal Residual Disease Testing Market?
What is the growth rate of the European Minimal Residual Disease Testing Market?
What is the forecasted size of the European Minimal Residual Disease Testing Market?
Who are the key companies in the European Minimal Residual Disease Testing Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 115 |
| Published | May 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 265.6 Million |
| Forecasted Market Value ( USD | $ 806.8 Million |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Europe |
Table of Contents
1 Introduction1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 Segmentation of Europe Market by Offering
3.1 Market Overview by Offering
3.2 Services
3.3 Test Kits & Consumables
4 Segmentation of Europe Market by Application
4.1 Market Overview by Application
4.2 Non-Hodgkin’s Lymphoma (NHL)
4.2.1 DLBCL
4.2.2 Marginal Zone Lymphoma
4.2.3 Follicular Lymphoma
4.2.4 Peripheral T-cell Lymphoma
4.2.5 Mantle Cell Lymphoma
4.2.6 Other NHLs
4.3 Multiple Myeloma (MM)
4.4 Acute Lymphoblastic Leukemia (ALL)
4.5 Chronic Lymphoblastic Leukemia (CLL)
4.6 Acute Myeloid Leukemia (AML)
4.7 Chronic Myeloid Leukemia (CML)
4.8 Hodgkin’s Lymphoma (HL)
4.9 Solid Tumor
4.10 Other Applications
5 Segmentation of Europe Market by Technology
5.1 Market Overview by Technology
5.2 Flow Cytometry
5.3 Polymerase Chain Reaction (PCR)
5.4 Next-Generation Sequencing (NGS)
5.5 Other Technologies
6 Segmentation of Europe Market by End User
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Research Institutions
6.4 Diagnostic Laboratories
6.5 Other End Users
7 European Market 2021-2031 by Country
7.1 Overview of European Market
7.2 Germany
7.3 U.K.
7.4 France
7.5 Spain
7.6 Italy
7.7 Netherlands
7.8 Rest of European Market
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
List of TablesTable 1. Snapshot of Europe Minimal Residual Disease Testing Market in Balanced Perspective, 2021-2031
Table 2. World Economic Outlook, 2021-2031
Table 3. World Health Spending by Region, $ bn, 2013-2020
Table 4. Main Product Trends and Market Opportunities in Europe Minimal Residual Disease Testing Market
Table 5. Europe Minimal Residual Disease Testing Market by Offering, 2021-2031, $ mn
Table 6. Europe Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 7. Europe Minimal Residual Disease Testing Market: Non-Hodgkin’s Lymphoma (NHL) by Type, 2021-2031, $ mn
Table 8. Europe Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 9. Main Vendors and Products of Flow Cytometry Technology
Table 10. Main Vendors and Products of Polymerase Chain Reaction (PCR) Technology
Table 11. Main Vendors and Products of Next-Generation Sequencing (NGS) Technology
Table 12. Europe Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 13. Europe Minimal Residual Disease Testing Market by Country, 2021-2031, $ mn
Table 14. Germany Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 15. Germany Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 16. Germany Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 17. U.K. Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 18. U.K. Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 19. U.K. Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 20. France Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 21. France Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 22. France Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 23. Spain Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 24. Spain Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 25. Spain Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 26. Italy Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 27. Italy Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 28. Italy Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 29. Netherlands Minimal Residual Disease Testing Market by Application, 2021-2031, $ mn
Table 30. Netherlands Minimal Residual Disease Testing Market by Technology, 2021-2031, $ mn
Table 31. Netherlands Minimal Residual Disease Testing Market by End User, 2021-2031, $ mn
Table 32. Minimal Residual Disease Testing Market in Rest of Europe by Country, 2021-2031, $ mn
Table 33. Breakdown of World Market by Key Vendor, 2021, %
Table 34. Approved and Launched MRD Testing Products of Key Vendors
Table 35. Adaptive Biotechnologies Corporation: Company Snapshot
Table 36. Adaptive Biotechnologies Corporation: Business Segmentation
Table 37. Adaptive Biotechnologies Corporation: Product PortfolioList of FiguresFigure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031
Figure 4. Europe Minimal Residual Disease Testing Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Europe Minimal Residual Disease Testing Market
Figure 7. World Number of Deaths from Cancers in 201
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060
Figure 10. Primary Restraints and Impact Factors of Europe Minimal Residual Disease Testing Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Five Forces Analysis of Europe Minimal Residual Disease Testing Market
Figure 13. Breakdown of Europe Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue
Figure 14. Europe Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%)
Figure 15. Europe Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn
Figure 16. Europe Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn
Figure 17. Breakdown of Europe Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue
Figure 18. Europe Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%)
Figure 19. Europe Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn
Figure 20. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn
Figure 21. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn
Figure 22. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn
Figure 23. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn
Figure 24. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn
Figure 25. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn
Figure 26. Europe Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn
Figure 27. Europe Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn
Figure 28. Europe Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn
Figure 29. Europe Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn
Figure 30. Europe Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn
Figure 31. Europe Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn
Figure 32. Europe Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn
Figure 33. Europe Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn
Figure 34. Breakdown of Europe Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue
Figure 35. Europe Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%)
Figure 36. Europe Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn
Figure 37. Europe Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn
Figure 38. Europe Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn
Figure 39. Europe Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn
Figure 40. Breakdown of Europe Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue
Figure 41. Europe Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)
Figure 42. Europe Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn
Figure 43. Europe Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn
Figure 44. Europe Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn
Figure 45. Europe Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn
Figure 46. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue
Figure 47. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 48. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn
Figure 49. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn
Figure 50. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn
Figure 51. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn
Figure 52. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn
Figure 53. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn
Figure 54. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn
Figure 55. Growth Stage of Europe Minimal Residual Disease Testing Industry over the Forecast Period
Companies Mentioned
A selection of companies mentioned in this report includes:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
Methodology
LOADING...
